Dae Gon Ha
Stock Analyst at Stifel
(1.70)
# 2,959
Out of 4,814 analysts
48
Total ratings
33.33%
Success rate
-1.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.29 | +133.46% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $69.95 | +5.79% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $3.06 | -1.96% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $0.92 | +1,630.85% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $7.27 | +780.94% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $168.53 | +30.54% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $38.63 | +70.85% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $35.64 | +256.34% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $4.84 | +333.88% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $4.61 | +768.62% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $6.33 | +658.29% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.24 | +1,357.49% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.47 | +1,398.93% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $61.65 | -59.45% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $6.83 | +134.43% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $9.86 | +2,790.47% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.15 | +1,646.72% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.04 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $18.17 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.39 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.06 | +1,032.08% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $7.76 | +6,214.43% | 2 | Oct 23, 2017 |
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.29
Upside: +133.46%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $69.95
Upside: +5.79%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $3.06
Upside: -1.96%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $0.92
Upside: +1,630.85%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $7.27
Upside: +780.94%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $168.53
Upside: +30.54%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $38.63
Upside: +70.85%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $35.64
Upside: +256.34%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $4.84
Upside: +333.88%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $4.61
Upside: +768.62%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $6.33
Upside: +658.29%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $1.24
Upside: +1,357.49%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.47
Upside: +1,398.93%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $61.65
Upside: -59.45%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $6.83
Upside: +134.43%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $9.86
Upside: +2,790.47%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.15
Upside: +1,646.72%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.04
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $18.17
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.39
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.06
Upside: +1,032.08%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $7.76
Upside: +6,214.43%